Applications of (R*,S*)-(-)-8-Hydroxy-5-(1-Hydroxy-2-((1-Methylethyl)Amino)Butyl)-2(1H)-Quinolinone in Industrial Manufacturing

As the direct manufacturer of this chiral quinolinone derivative, we support advanced downstream synthesis across pharmaceutical, veterinary, and related fine chemical sectors. Each sector applies this raw material in distinct regulated processes, using precise formulation controls and strict compliance standards throughout scale-up and industrial implementation.

1. Active Pharmaceutical Ingredient Synthesis for Cardiovascular Drug Intermediates

Pharmaceutical producers integrate this compound in the multi-step synthesis of selective β2-adrenergic agonist intermediates, including those structurally related to salbutamol and similar therapies. Its high enantiomeric purity is essential for achieving rigorous product specifications and regulatory submissions in tablet, inhaler, and injectable formulation projects. Plant chemists handle the compound during reaction stages such as amide coupling, chiral resolution, or downstream protection/deprotection, followed by quality control to meet pharmacopoeia standards.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs applicable to chiral drug substances
• US FDA cGMP (21 CFR Parts 210 & 211)
• ISO 9001:2015 for quality management systems in pharmaceutical production

Typical usage ratio

• 0.5 – 2.5 molar equivalents per batch depending on downstream target
• Stoichiometry adjusted based on yield, chiral purity goals, and impurity profile monitoring
• Batch sizes typically range from 10g lab to 100+ kg commercial scale
• Lower concentrations for route scouting, higher end for pilot and validation batches

Downstream process integration

• Input during chiral intermediate coupling steps
• Combined with suitable reagents in enantioselective transformations
• Processed under inert atmosphere with precise temperature control
• QC sampling for HPLC-based purity and assay after each reaction stage

Final product types

• Cardiovascular APIs (e.g., β-agonists)
• Finished oral and inhaled prescription drug formulations
• Pharma-grade intermediates for regulated market supply
• Research compounds for drug development pipelines

2. Synthesis of Bronchodilator Intermediates for Respiratory Medicines

Industrial process chemists utilize this material for producing advanced intermediates in the synthesis of bronchodilators. Its chemical structure supports high-yield conversion during etherification and subsequent methylation stages, essential for respiratory medicine supply chains. Downstream producers apply strict in-process monitoring of chiral purity, crucial for achieving consistent pharmacological profiles and meeting EU and FDA regulatory audits.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) guidelines for bronchodilator APIs
• US Pharmacopeia (USP) standards on beta-agonists and intermediates
• PIC/S GMP guides for pharmaceutical manufacturing
• ISO 14001 for environmental controls in chemical processing

Typical usage ratio

• 1.0 – 2.0 molar equivalents vs. starting aromatic precursors
• Adjusted according to impurity control and final API throughput
• Process chemists may optimize ratios for improved conversion in scale-up
• Usage documented and justified in technical transfer dossiers

Downstream process integration

• Reactant in stepwise synthesis of chiral bronchodilator scaffolds
• Combined with base and electrophile during etherification
• Purification by preparative chromatography for enantiomer enrichment
• Process parameter documentation aligned with DMF/CTD requirements

Final product types

• Bulk intermediates for bronchodilator active ingredients
• Finished APIs applied in asthma and COPD medications
• Technical-grade intermediates for further contract manufacturing
• Reference standards for pharmaceutical QC laboratories

3. Fine Chemical Building Block for Agrochemical Synthesis

Agrochemical manufacturers adopt this hydroxy-quinolinone derivative as a building block in the route synthesis of advanced crop protection compounds, especially for chiral amine-containing fungicides and herbicides. The stable structure allows for direct substitution, acylation, or coupling chemistry under controlled reactors. Formulators monitor raw material ratios, impurity flags, and physical property endpoints to ensure the downstream crop safety and agrochemical registration compliance.

Industry compliance standards

• FAO/WHO specifications for pesticide quality
• REACH (EC) No 1907/2006 regulation for chemical substance registration in the EU
• ISO 17025 accredited analytical testing for lot release
• GLP (Good Laboratory Practice) for process documentation

Typical usage ratio

• 0.2 – 0.8 weight equivalents against total reaction feed in synthesis lines
• Ratio fine-tuned for desired bioactivity and minimization of waste
• Adjusted during pilot to commercial transitions
• Usage tracked for chemical registration and environmental residue documentation

Downstream process integration

• Charged into chiral amine functionalization steps in batch or semi-continuous reactors
• Mixed with alkylating or acylating reagents under monitored pH and pressure
• Processed through distillation, phase separation, or crystallization prior to isolation
• Sampled for GC/MS-based impurity control and target spectrum verification

Final product types

• Registered active substances for crop protection
• Fungicide and herbicide intermediates sold to formulation plants
• Precursor batches for pilot field trials
• Technical concentrate products for downstream toll processing

4. Intermediate for Veterinary Drug Formulations

Veterinary pharmaceutical companies use this chiral intermediate in the synthesis of active substances that target respiratory and cardiovascular disorders in companion and farm animals. Manufacturing sites implement dosage-specific synthesis steps, often employing protected group strategies to maintain molecular integrity under process conditions. The downstream utility of the intermediate enables consistent therapeutic outcomes in finished animal medicines, with full traceability and adherence to VICH guidelines.

Industry compliance standards

• VICH GL9 Good Manufacturing Practices for active pharmaceutical ingredients
• China Veterinary Pharmacopoeia (CVP) for compound-specific requirements
• US FDA CVM guidelines for veterinary drug intermediates
• Veterinary International Conference on Harmonization (VICH) requirements

Typical usage ratio

• 0.7 – 1.3 molar equivalents per batch, depending on target animal species
• Adjusted for end-use dosage form (oral, injectable, bolus)
• Batch protocols established during process validation
• Ratio supported by process analytical technology (PAT)

Downstream process integration

• Charged during key coupling step in multi-stage veterinary API synthesis
• Subjected to filtration, solvent exchanges, or salt formation as needed per formulation spec
• Quality controlled for residues, trace elements, and stereochemical purity
• Samples retained for regulatory submissions and batch records

Final product types

• Veterinary bulk APIs for injectable and oral drugs
• Animal health oral powder premixes
• Injectable veterinary medicines produced under GMP
• Finished veterinary drugs for farm and companion animals